1. Home
  2. ONON vs IMVT Comparison

ONON vs IMVT Comparison

Compare ONON & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo On Holding AG

ONON

On Holding AG

N/A

Current Price

$28.05

Market Cap

10.4B

ML Signal

N/A

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$39.36

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONON
IMVT
Founded
2010
2018
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Shoe Manufacturing
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.4B
8.5B
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
ONON
IMVT
Price
$28.05
$39.36
Analyst Decision
Strong Buy
Buy
Analyst Count
20
8
Target Price
$60.15
$33.00
AVG Volume (30 Days)
9.1M
1.1M
Earning Date
05-12-2026
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$19.58
N/A
Revenue Next Year
$19.98
N/A
P/E Ratio
$56.05
N/A
Revenue Growth
N/A
N/A
52 Week Low
$27.56
$14.58
52 Week High
$51.08
$45.42

Technical Indicators

Market Signals
Indicator
ONON
IMVT
Relative Strength Index (RSI) 29.90 38.14
Support Level N/A $37.16
Resistance Level $39.02 $41.22
Average True Range (ATR) 0.80 1.52
MACD -0.10 -0.68
Stochastic Oscillator 11.18 6.53

Price Performance

Historical Comparison
ONON
IMVT

About ONON On Holding AG

Founded in Switzerland in 2010, sportswear firm On Holding generates more than 90% of its sales from athletic shoes. The brand is best known for its running shoes and its distinctive CloudTec soles. On also produces athletic apparel (6% of 2025 sales) and accessories (1%). The firm's merchandise is available in more than 80 countries and is sold through both wholesale (58% of sales) and company-owned channels (42%). In 2025, On generated 58% of its sales in North America, 25% in Europe, the Middle East, and Africa, and 17% in the Asia-Pacific region.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Share on Social Networks: